

REMARKS

Reconsideration is requested.

Claims 1, 15, 16, 22-24, 32, 36, 37, 40, 41, 48, 50, 51, 57, 58 and 62-69 are pending.

Claims 66-69 have been added and find support in the specification on pages 25-26.

The status of claim 33 has been corrected above. The Examiner's helpful suggestions in this regard are acknowledged, noted with appreciation.

Claim 32 has been amended to obviate the Section 112, second paragraph, rejections of the same. Withdrawal of the rejections are requested.

The specification has been amended on pages 8-9 to correct the inconsistency noted by the Examiner.

The specification has been revised with regard to the use of trademarks.

The Examiner's comments relating to the Patent Office's preferred arrangement of the specification are noted. As the noted headings are not mandatory, and the specification includes a heading related to the drawings, and the present specification is an English translation of the parent PCT application, the applicants submit, with due respect, that the specification is complete with regard to form required by the Rules and MPEP.


Withdrawal of the objections to the specification is requested.


To the extent not obviated by the above amendments, the Section 112, second paragraph, rejection of claims 1, 15, 16, 22-24, 32, 36, 37, 40, 41, 50, 51, 58 and 62-64

is traversed. Reconsideration and withdrawal of the rejection are requested.

Consideration of the following further comments in this regard are requested.

SEQ ID NOs: 9 and 54 are reproduced below wherein the relationship of these sequences to SEQ ID NOs: 3-8 is demonstrated.





The amino acid sequences of SEQ ID NOs:3, 4 and 5 correspond to amino acids 31 to 35, amino acids 50 to 66 and amino acids 99 to 108, respectively, of the amino acid sequence of SEQ ID NO:9. SEQ ID NO:9 therefore includes the CDR1, CDR2 and CDR3 of the H chain V region represented separately by SEQ ID NOs: 3, 4 and 5. Similarly, the amino acid sequences of SEQ ID NOs:6, 7 and 8 correspond to amino acids 24 to 34, amino acids 50 to 56 and amino acids 89 to 97, respectively, in the amino acid sequence of SEQ ID NO:54. SEQ ID NO:54 therefore includes the CDR1, CDR2 and CDR3 of the L chain V region represented separately by SEQ ID NOs: 6, 7 and 8.

Claim 1 has been revised to provide for the following four (4) alternative combinations:

(a) CDR1, CDR2 and CDR3 of H chain V region having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively, and CDR1, CDR2 and

CDR3 of L chain V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively,

(b) CDR1, CDR2 and CDR3 of H chain V region having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively, and an L chain V region having the amino acid sequence represented by SEQ ID NO:54,

(c) an H chain V region having the amino acid sequence represented by SEQ ID NO:9; and CDR1, CDR2 and CDR3 of L chain V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively, and

(d) an H chain V region having the amino acid sequence represented by SEQ ID NO:9; and an L chain V region having the amino acid sequence represented by SEQ ID NO:54.

In response to the Examiner's inquiry, the applicants note that the transformant KM8871 (FERM BP-6790) produces a humanized antibody comprising the heavy chain CDRs of SEQ ID NOs: 3-5 and heavy chain CDRs of SEQ ID NO:9 in that the CDRs of SEQ ID NO:9 are the CDRs of SEQ ID NOs:3-5, as noted schematically above. Moreover, the transformant KM8871 (FERM BP-6790) produces a humanized antibody comprising the light chain CDRs of SEQ ID NOs: 6-8 and light chain CDRs of SEQ ID NO:54 in that the CDRs of SEQ ID NO:54 are the CDRs of SEQ ID NOs:6-8, as noted schematically above. The Examiner is requested to see page 21, second full paragraph, of the specification in this regard.

Claim 41 has been revised to indicate that the H chain V region of SEQ ID NO:53 is SEQ ID NO:9, which represents amino acids 1-119 of SEQ ID NO:53.

Finally, the applicants submit, with due respect, that one of ordinary skill in the art will appreciate the metes and bounds of the recited therapeutic agent within the context of an antibody conjugate of the claims. The new claims have been added to recite specific therapeutic agents of the disclosure.

The claims are submitted to be definite and withdrawal of the Section 112, second paragraph, rejection is requested.

The Section 112, first paragraph, rejection of claims 1, 15, 16, 24, 36, 37, 50, 51, 63 and 64 is obviated by the above amendments. Reconsideration and withdrawal of the rejection is requested in view of the above amendments and comments. The claims are submitted to be supported by an adequate written description.

The claims are submitted to be in condition for allowance and a Notice to that effect is requested. The Examiner is requested to contact the undersigned in the event anything further is required in this regard.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
 B. J. Sadoff
 Reg. No. 36,663

BJS:
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100